Anaemia is the common comorbidity in patients with chronic kidney disease (CKD). Clinical studies have shown that erythropoietin-stimulating agents decrease the need for transfusions and improve the quality of life. The objectives were to assess prevalence of anemia and its management. A prospective, hospital based study was conducted for a period of six months on 100 dialysis patients suffering from anaemia in chronic renal failure condition. A written informed consent was obtained from all the patients before inclusion in the study. Patient demographics, laboratory data and treatment chart were reviewed. The study results were analyzed by descriptive statistical analysis. Student t test was used to find significance of study parameters. Hemoglobin level was found to be significantly lower in CKD cases than in non-CKD cases. Anaemia was seen in all stages of CKD, severity of anaemia increased as kidney function detoriates. Anaemia in CKD is better treated with erythropoietin as well as iron sucrose. Prevalence of anaemia was strongly associated with declining glomerular filtration rate, which is more frequent at higher stages. It can be concluded that early detection and treatment of anemia has effective benefits in chronic kidney disease patients. Management includes erythropoietin stimulating agents as well as blood transfusion.
Loading....